Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...
Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...
Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s ...
Extends Gratitude to Outgoing Board Members for Their Years of Dedicated Service to the IMF BoardSTUDIO CITY, Calif., Nov. 26 ...
GlobalData on MSN2d
GSK eyes up combo approval for previously withdrawn myeloma drugThe US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...
Experience convenient blood cancer treatment close to home. Find out how this unique partnership brings autologous stem cell ...
2d
GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...
A ground breaking study mapping the immune microenvironment in Multiple Myeloma identifies critical immune changes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback